# The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

> **NCT01942993** · PHASE2 · TERMINATED · sponsor: **Philip Friedlander** · enrollment: 3 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01942993
- **Lead sponsor:** Philip Friedlander
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** standard of care has changed
- **Last updated:** 2020-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01942993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01942993, "The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01942993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*